2 results
Approved WMOCompleted
To demonstrate that treatment with drotrecogin alfa (activated) 24 mcg/kg/h administered as an intravenous infusion for 96 hours reduces 28 day all-cause mortality in adult patients with septic shock compared with placebo.
Approved WMOCompleted
The aim of the study is to evaluate the efficacy of sensor augmented pump (SAP) therapy with MiniMed* 640G and SmartGuard* in preventing hypoglycemic events in comparison with continuous subcutaneous insulin infusion (CSII) therapy in type 1…